Onesource Specialty Pharma credit ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025


1,276	1,276	772
1,173	1,173	462
0.22×	0.22×	0.13×
0.20×	0.20×	0.08×
4.20×	4.20×	1.65×
2.96×	3.86×	0.99×
0.21×	0.21×	1.16×
17.7%	18.0%	11.6%
—	—	0.16×
—	—	0.63×
—	—	1.52×

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ONESOURCE₹1,569.60

Onesource Specialty Pharma Ltd.

· Pharma & Health

₹ CrorePeersSTAR DIVISLAB GLAND PFIZER POLYMED RAINBOW KIMS JUBLPHARMAMcap ₹17,991 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Total Debt	771.6	1,276.3	1,276.3
Net Debt	461.8	1,173.3	1,173.3
Total Debt/Equity	0.13	0.22	0.22
Net Debt/Equity	0.08	0.20	0.20
Total Debt/EBITDA	1.65	4.20	4.20
Net Debt/EBITDA	0.99	3.86	2.96
Interest Coverage (EBIT/Interest)	1.16	0.21	0.21
Total Debt/Total Capital %	11.60	17.96	17.73
As Filed — company-reported covenants
Debt/Equity (as filed)	0.16	—	—
Debt Service Coverage (as filed)	0.63	—	—
Interest Service Coverage (as filed)	1.52	—	—

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.